{
    "clinical_study": {
        "@rank": "40243", 
        "arm_group": [
            {
                "arm_group_label": "Cases", 
                "description": "Children hospitalised for SGE, aged 12 weeks to < 5 years at the time of hospital admission/ED stay and whose stool samples test positive for RV by enzyme linked immunosorbent assay (ELISA) at a GSK designated laboratory."
            }, 
            {
                "arm_group_label": "Controls", 
                "description": "Children hospitalised for SGE, aged 12 weeks to < 5 years at the time of hospital admission/ ED stay, whose stool samples test negative for RV by enzyme linked immunosorbent assay at a GSK designated laboratory and who will be matched to the cases by date of birth and the hospital of admission/ ED stay."
            }
        ], 
        "biospec_descr": {
            "textblock": "Stool sample"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "This study aims to estimate the effectiveness of Rotarix\u2122 vaccine against Rotavirus severe\n      gastroenteritis (RV SGE) among hospitalised children aged between 12 weeks and < 5 years, in\n      Venezuela and to assess the current disease burden after introduction of the vaccine."
        }, 
        "brief_title": "Effectiveness of RotarixTM Vaccine in Children Aged Between 12 Weeks to < 5 Years, Hospitalised for Severe Gastroenteritis", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Infections, Rotavirus", 
        "condition_browse": {
            "mesh_term": [
                "Gastroenteritis", 
                "Rotavirus Infections"
            ]
        }, 
        "detailed_description": {
            "textblock": "The data generated in this study will be useful for public health officers and policy makers\n      in confirming the country-wide public health benefit of Rotarix\u2122.\n\n      No vaccine will be administered during this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        For SGE subjects:\n\n          -  A male or female child aged 12 weeks to < 5 years at the time of hospital admission/\n             ED stay. The subject becomes ineligible on the fifth birthday.\n\n          -  Subject admitted to (or who will have an ED stay at) the study hospital(s) for SGE\n             during the study period.\n\n          -  Onset of SGE \u2264 14 days prior to admission/ ED stay.\n\n          -  Written/thumb printed informed consent obtained from the parent(s)/legally acceptable\n             representative(s) (LAR (s)) of the subject.\n\n        For Cases:\n\n        \u2022  Laboratory confirmed (i.e. by ELISA) RV-positive stool sample collected at hospital\n        admission/ ED stay or during the first 48 hours of hospitalisation.\n\n        For Controls:\n\n          -  Subject admitted to (or who will have an ED stay at) the same study hospital(s) for\n             SGE as that of the case during the study period.\n\n          -  Laboratory confirmed (i.e. by ELISA) RV-negative stool sample collected at hospital\n             admission/ ED stay or during the first 48 hours of hospitalisation.\n\n          -  Subjects born within \u00b1 2 weeks from the date of birth of the case.\n\n        Exclusion Criteria:\n\n        For SGE subjects:\n\n          -  Child in care.\n\n          -  Hospitalisation is unrelated to GE.\n\n          -  Onset of SGE > 48 hours after admission to (or ED stay at) the hospital.\n\n          -  Subject has digestive tube anomalies, chronic gastrointestinal disease or uncorrected\n             congenital abnormalities.\n\n          -  Subject with immunodeficiency.\n\n          -  Subjects who live out of the federative entity where hospital(s) are located.\n\n        For Controls:\n\n        \u2022  Subject has previously participated as case in this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "5 Years", 
            "minimum_age": "12 Weeks", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Children aged 12 weeks to < 5 years, hospitalised for SGE in the study hospitals."
            }
        }, 
        "enrollment": {
            "#text": "1500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01978223", 
            "org_study_id": "116494"
        }, 
        "intervention": {
            "arm_group_label": [
                "Controls", 
                "Cases"
            ], 
            "description": "Stool samples will be collected from all children enrolled in the study, within 48 hours of admission to the hospital/ ED.  Stool samples will be tested to determine the presence or absence of rotavirus (RV). Additionally, for RV-positive cases, the stool samples will be tested to determine the RV genotypes.", 
            "intervention_name": "Stool sample collection", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Children", 
            "Vaccine effectiveness", 
            "Hospitalised", 
            "Venezuela", 
            "Rotavirus Severe Gastroenteritis", 
            "Case-control", 
            "Rotarix\u2122"
        ], 
        "lastchanged_date": "April 17, 2014", 
        "number_of_groups": "2", 
        "official_title": "Case-control Study to Evaluate the Vaccine Effectiveness of RotarixTM Against Rotavirus Severe Gastroenteritis Among Hospitalised Children Aged 12 Weeks to < 5 Years, in Venezuela", 
        "overall_contact": {
            "email": "GSKClinicalSupportHD@gsk.com", 
            "last_name": "US GSK Clinical Trials Call Center", 
            "phone": "877-379-3718"
        }, 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Venezuela: Institutional Review Board"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Full vaccination status of Rotarix\u2122 (2 doses) with the vaccine administered at least 2 weeks before hospitalisation in RV-positive SGE children (cases) compared to RV-negative SGE children (controls).", 
            "safety_issue": "No", 
            "time_frame": "During hospitalisation and after discharge (approximately 12 months from study initiation)."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01978223"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Full/partial vaccination status (at least one dose of Rotarix\u2122) with the vaccine administered at least 2 weeks before hospitalisation in RV-positive SGE children (cases) compared to RV-negative SGE children (controls).", 
                "safety_issue": "No", 
                "time_frame": "During hospitalisation and after discharge (approximately 12 months from study initiation)."
            }, 
            {
                "measure": "Occurrence of specific RV genotype among the enrolled RV SGE children with full/partial vaccination status (at least one dose of Rotarix\u2122 with the vaccine is administered at least 2 weeks before hospitalisation).", 
                "safety_issue": "No", 
                "time_frame": "During hospitalisation and after discharge (approximately 12 months from study initiation)."
            }, 
            {
                "measure": "Occurrence of RV SGE in children by age at hospitalisation with full/partial vaccination status (at least one dose of Rotarix\u2122 with the vaccine administered at least 2 weeks before hospitalisation).", 
                "safety_issue": "No", 
                "time_frame": "During hospitalisation and after discharge (approximately 12 months from study initiation)."
            }, 
            {
                "measure": "Occurrence of RV SGE in children by severity with assessment of severity of RV SGE cases by the Vesikari scale.", 
                "safety_issue": "No", 
                "time_frame": "During hospitalisation and after discharge (approximately 12 months from study initiation)."
            }, 
            {
                "measure": "Occurrence of SGE [\u226414 days prior to admission/ Emergency Department (ED) stay] among all hospitalised children.", 
                "safety_issue": "No", 
                "time_frame": "During hospitalisation and after discharge (approximately 12 months from study initiation)."
            }, 
            {
                "measure": "Occurrence of RV SGE hospital admissions/ ED stays among children hospitalised at the study hospital(s) for SGE.", 
                "safety_issue": "No", 
                "time_frame": "At hospital admission/ ED stay or during the first 48 hours of hospitalisation."
            }, 
            {
                "measure": "Occurrence of RV SGE admissions/ ED stays by age of the child (at hospitalisation) and month of year.", 
                "safety_issue": "No", 
                "time_frame": "During hospitalisation and after discharge (approximately 12 months from study initiation)."
            }, 
            {
                "measure": "Occurrence of RV genotypes among children admitted to (or who have had an ED stay at) the study hospital(s) for SGE.", 
                "safety_issue": "No", 
                "time_frame": "During hospitalisation and after discharge (approximately 12 months from study initiation)."
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2014", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}